193 related articles for article (PubMed ID: 34431518)
21. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
22. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
23. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S; Takahashi T; Tamagawa H; Nakamura M; Munemoto Y; Kato T; Hata T; Denda T; Morita Y; Inukai M; Kunieda K; Nagata N; Kurachi K; Ina K; Ooshiro M; Shimoyama T; Baba H; Oba K; Sakamoto J; Mishima H
Ann Oncol; 2015 Jul; 26(7):1427-33. PubMed ID: 25908603
[TBL] [Abstract][Full Text] [Related]
24. Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Kullmann F; Scheithauer W; Scholz M; Müller S; Link H; Rost A; Höffkes HG; Moehler M; Lindig RU; Miller-Phillips L; Kirchner T; Jung A; von Einem JC; Modest DP; Heinemann V
Int J Cancer; 2018 Mar; 142(5):1047-1055. PubMed ID: 29047142
[TBL] [Abstract][Full Text] [Related]
25. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
[TBL] [Abstract][Full Text] [Related]
26. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
[TBL] [Abstract][Full Text] [Related]
27. First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab.
Odabas H; Ozdemir N; Abali H; Oksuzoglu B; Isik M; Uncu D; Cihan S; Seker M; Zengin N
J BUON; 2011; 16(2):247-52. PubMed ID: 21766493
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
[No Abstract] [Full Text] [Related]
29. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
30. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
32. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S; Rosati G; Nasti G; Lonardi S; Zaniboni A; Marchetti P; Leone F; Bilancia D; Iaffaioli RV; Zagonel V; Giordano M; Corsi DC; Ferraú F; Labianca R; Ronzoni M; Scartozzi M; Galli F;
Eur J Cancer; 2017 Sep; 83():106-115. PubMed ID: 28735067
[TBL] [Abstract][Full Text] [Related]
33. Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
Froelich MF; Petersen EL; Heinemann V; Nörenberg D; Hesse N; Gesenhues AB; Modest DP; Sommer WH; Hofmann FO; Stintzing S; Holch JW
Clin Colorectal Cancer; 2020 Dec; 19(4):291-300.e5. PubMed ID: 32917529
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Krebs MG; Renehan AG; Backen A; Gollins S; Chau I; Hasan J; Valle JW; Morris K; Beech J; Ashcroft L; Saunders MP; Dive C
Clin Colorectal Cancer; 2015 Jun; 14(2):115-22.e1-2. PubMed ID: 25680623
[TBL] [Abstract][Full Text] [Related]
35. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
36. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
37. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
38. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S; Dobi E; Jary M; Monnien F; Curtit E; Nguyen T; Lakkis Z; Heyd B; Fratte S; Cléau D; Lamfichekh N; Nerich V; Guiu B; Demarchi M; Borg C
BMC Cancer; 2013 Dec; 13():611. PubMed ID: 24373251
[TBL] [Abstract][Full Text] [Related]
39. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
